<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04160130</url>
  </required_header>
  <id_info>
    <org_study_id>RHEIA</org_study_id>
    <secondary_id>CIV-19-11-030544</secondary_id>
    <nct_id>NCT04160130</nct_id>
  </id_info>
  <brief_title>RHEIA (Randomized researcH in womEn All Comers With Aortic Stenosis)</brief_title>
  <acronym>RHEIA</acronym>
  <official_title>A Prospective, Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Transcatheter Aortic Valve Implantation in Female Patients Who Have Severe Symptomatic Aortic Stenosis Requiring Aortic Valve Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SSS International Clinical Research GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>SSS International Clinical Research GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of this prospective, randomized, controlled, multi-center study is to evaluate the&#xD;
      safety and efficacy of Transcatheter Aortic Valve Implantation (TAVI) as compared to surgical&#xD;
      aortic valve replacement (SAVR) in female patients with severe symptomatic aortic stenosis.&#xD;
      Patients will be randomized 1:1 to receive either TAVI or SAVR aortic valve replacement. For&#xD;
      TAVI procedure, Edwards SAPIEN 3 THV system Model 9600 TFX (20, 23, 26 and 29 mm) or SAPIEN 3&#xD;
      Ultra THV system Model 9750 TFX (20, 23, 26) with the associated transfemoral delivery&#xD;
      systems will be sued, for SAVR any commercially available surgical bioprosthetic valve.&#xD;
      Patients will undergo the following visits: Screening, Procedure, Post Procedure, Discharge,&#xD;
      30 day, 6 months (telephone contact) and 1 year.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent large meta-analyses and a large retrospective study from the STS/ACC TVT Registry&#xD;
      demonstrated improved survival in female versus male aortic sclerosis patients undergoing&#xD;
      TAVI despite their advanced age and increased rates of major peri-procedural vascular&#xD;
      complications, bleeding events and strokes. These gender-related patient profile differences&#xD;
      have also been present in multicentre cohorts across the world. A recent meta-analysis by&#xD;
      Siontis et al. showed that TAVI, when compared with SAVR, was associated with a significant&#xD;
      13% relative risk reduction in 2-year mortality, a benefit more pronounced amongst females&#xD;
      and patients undergoing transfemoral TAVI.&#xD;
&#xD;
      In a recent meta-analysis, the female-specific survival advantage from TAVI over SAVR was&#xD;
      explored. Amongst females, TAVI recipients had a significantly lower mortality than SAVR&#xD;
      recipients, at 1 year (OR 0.68; 95%CI 0.50 to 0.94). Amongst males there was no difference in&#xD;
      mortality between TAVI and SAVR at 1 year (OR 1.09; 95%CI 0.86 to 1.39). There was&#xD;
      statistically significant evidence of a difference in treatment effect between genders at 1&#xD;
      year (p interaction = 0.02). In an attempt to explore the mechanisms for an increased&#xD;
      mortality rate in women undergoing SAVR, different endpoints were explored in female patients&#xD;
      exclusively. It was shown that women, undergoing SAVR, having both a higher periprocedural&#xD;
      mortality, higher rates of bleeding and acute kidney injury, worse patient prosthesis match&#xD;
      and worse long term recovery of left ventricular function.In the recent PARTNER 3 the&#xD;
      composite of death from any cause, stroke, or rehospitalization had occurred in 42 patients&#xD;
      (8.5%) in the TAVI group as compared with 68 patients (15.1%) in the surgery group at 1 year.&#xD;
      The difference was 6.6% (95%CI -10.8% to -2.3%) and thus exceeded the pre-defined&#xD;
      non-inferiority margin of 6%.&#xD;
&#xD;
      Subgroup analyses of the primary end point at 1 year showed no heterogeneity of treatment&#xD;
      effect in any of the subgroups that were examined including gender (p=0.27). There were 292&#xD;
      women included with an endpoint rate of 18.5% for SAVR (men 13.8%) and 8.1% for TAVI (men&#xD;
      8.7%), showing a clear trend for an increased benefit of women undergoing TAVI instead of&#xD;
      SAVR (rate difference -10.4%; 95%CI -18.3% to -2.5%). Nonetheless, the benefits of TAVI were&#xD;
      preserved in both men and women.Earlier observational and clinical studies indicated an&#xD;
      increased risk for women undergoing SAVR compared to men while being at a comparable risk for&#xD;
      TAVI. In a recent meta-analysis of TAVI vs. SAVR in men and women the risk of dying from the&#xD;
      intervention was reduced by a relative 32% in women (OR 0.38; 95%CI 0.50-0.94) while there&#xD;
      was no such difference in men (OR 1.09; 95%CI 0.86-1.39). This was mostly documented as being&#xD;
      the effect of a reduced periprocedural mortality with TAVI (-54%; OR 0.46; 95%CI 0.22-0.96)&#xD;
      and major bleeding (-57%; OR 0.43; 95%CI 0.25-0.73) while the difference in strokes and acute&#xD;
      kidney injury did not reach statistical significance. Taken all available scientific data on&#xD;
      the comparison of TAVI versus open surgery in patients with indication for AVR together it&#xD;
      remains probable, that independently of the individual surgical risk female patients in&#xD;
      particular seem to benefit from a non-surgical aortic valve replacement strategy.&#xD;
&#xD;
      As the indirect comparisons of the intermediate to low risk outcomes in PARTNER 2/3 suggest a&#xD;
      favorable risk reduction in women compared to men as described, the investigators believe it&#xD;
      is timely for a dedicated trial to demonstrate the non-inferiority of TAVI in women compared&#xD;
      to SAVR and, in case of this being true, whether TAVI is actually superior to performing&#xD;
      SAVR.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 29, 2019</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Number of patients with death of any cause (death due to proximate cardiac cause, death caused by non-coronary vascular conditions, procedure-related deaths, valve-related deaths, sudden or unwitnessed death, non-cardiovascular mortality, death of unknown cause)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stroke</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Number of patients with stroke (disabling and non-disabling).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Re-hospitalization</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Number of patients with re-hospitalization (valve-related or procedure-related or worsening of congestive heart failure).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of Index hospitalization</measure>
    <time_frame>through day of procedure until day of discharge</time_frame>
    <description>Number of days per patient for index hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prosthesis-patient mismatch</measure>
    <time_frame>up to 30 days post-procedure</time_frame>
    <description>Number of patients with a prosthesis mismatch.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New onset atrial fibrillation</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Number of patients with a new onset of atrial fibrillation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular complications</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Number of patients with major vascular complications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding complications</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Number of patients with life-threatening, disabling, or major bleeding complications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Number of patients with new myocardial infarction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute kidney injury</measure>
    <time_frame>up to 30 days post-procedure</time_frame>
    <description>Number of patients with new onset of acute kidney injury stage II/III (AKIN classification).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute kidney injury</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Number of patients with the need of renal replacement therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New permanent pacemaker implantation</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Number of patients with new permanent pacemaker implantation caused by new or worsened conduction disturbances.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in New York Heart Association (NYHA) classification</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Severity of cardiac disease based on functional capacity will be described using the NYHA classification. Classification ranges from I - IV, with the lowest (I) as no limitations and the highest (IV) unable to carry on any physical activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemodynamic valve performance</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Hemodynamic valve performance will be evaluated by echocardiography for aortic valve stenosis and aortic valve regurgitation (paravalvular &amp; central).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in impairment caused by a stroke</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Impairment caused by a stroke will be assessed using the the National Institutes of Health Stroke Scale (NIHSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cognitive function</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Cognitive function will be assessed using the Mini-mental state Examination-2 (MMSE-2) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the degree of disability in the daily activities</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Degree of disability in the daily activities will be assessed using the modified Rankin Scale (mRS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Frailty Index</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Frailty index will be assessed by the 5 Meter Walk Test, grip strength, Instrumental Activities of Daily Living and serum Albumin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in disease-specific health status</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>The health status in regards to congestive heart failure will be assessed by the patient using the Kansas City Cardiomyopathy Questionnaire (KCCQ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in health-related quality of life</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>The health-related Quality of Life will be assessed by the patient using The Medical Outcomes Study Short-Form 12 (SF-12) questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Heart Valve Diseases</condition>
  <arm_group>
    <arm_group_label>SAPIEN 3 or SAPIEN 3 Ultra</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Edwards SAPIEN 3 THV system Model 9600 TFX (20, 23, 26 and 29 mm) or SAPIEN 3 Ultra THV system Model 9750 TFX (20, 23, 26) with the associated transfemoral delivery systems.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>any surgical bioprosthetic aortic valve</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Any commercially available surgical bioprosthetic valve</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transcatheter aortic valve replacement</intervention_name>
    <description>Patients will be randomized 1:1 to receive either transcatheter aortic valve replacement (TAVI) or aortic valve replacement with a commercially available surgical bioprosthetic valve.</description>
    <arm_group_label>SAPIEN 3 or SAPIEN 3 Ultra</arm_group_label>
    <arm_group_label>any surgical bioprosthetic aortic valve</arm_group_label>
    <other_name>Surgical aortic valve replacement</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female patients with severe aortic stenosis as follows:&#xD;
&#xD;
             • High gradient severe AS (Class I Indication for aortic valve replacement [AVR]): Jet&#xD;
             velocity ≥ 4.0 m/s or mean gradient ≥ 40 mmHg with Aortic Valve Area (AVA) ≤ 1.0 cm^2&#xD;
             or AVA index ≤ 0.6 cm^2/m^2 OR&#xD;
&#xD;
             • Low gradient severe aortic stenosis (Class I/IIa indication of AVR) Jet velocity &lt;&#xD;
             4.0 m/s and mean gradient &lt; 40 mmHg and AVA ≤ 1.0 cm^2 and AVA index ≤ 0.6 cm^2/m^2&#xD;
             with confirmation of severe AS by: mean gradient ≥40 mmHg on dobutamine stress&#xD;
             echocardiography and/or aortic valve calcium score ≥ 1200 AU on non-contrast CT.&#xD;
&#xD;
             AND&#xD;
&#xD;
               -  NYHA Functional Class ≥ II OR&#xD;
&#xD;
               -  Exercise test that demonstrates a limited exercise capacity, abnormal BP&#xD;
                  response, or arrhythmia&#xD;
&#xD;
          2. Age ≥ 18 years&#xD;
&#xD;
          3. The study patient has been informed of the nature of the study, agrees to its&#xD;
             provisions and has provided written informed consent as approved by the Institutional&#xD;
             Review Board (IRB)/Ethics Committee (EC) of the respective clinical site.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient is not a candidate for both surgical and transcatheter aortic valve&#xD;
             replacement.&#xD;
&#xD;
          2. Native aortic annulus size unsuitable for sizes 20, 23, 26, or 29 mm THV based on 3D&#xD;
             imaging analysis&#xD;
&#xD;
          3. Iliofemoral vessel characteristics that would preclude safe placement of the&#xD;
             introducer sheath.&#xD;
&#xD;
          4. Evidence of an acute myocardial infarction ≤ 1 month (30 days) before randomization&#xD;
&#xD;
          5. Aortic valve is unicuspid, bicuspid, or is non-calcified&#xD;
&#xD;
          6. Severe aortic regurgitation (&gt;3+)&#xD;
&#xD;
          7. Any concomitant valve disease that requires an intervention&#xD;
&#xD;
          8. Pre-existing mechanical or bioprosthetic valve in any position (mitral ring is not an&#xD;
             exclusion).&#xD;
&#xD;
          9. Complex coronary artery disease:&#xD;
&#xD;
               -  Unprotected left main coronary artery stenosis&#xD;
&#xD;
               -  Syntax score &gt; 32 (in the absence of prior revascularization)&#xD;
&#xD;
               -  Heart Team assessment that optimal revascularization cannot be performed.&#xD;
&#xD;
         10. Symptomatic carotid or vertebral artery disease or successful treatment of carotid&#xD;
             stenosis within 30 days before randomization&#xD;
&#xD;
         11. Leukopenia (WBC &lt; 3000 cell/mcL), anemia (Hgb &lt; 9 g/dL), Thrombocytopenia (Plt &lt;&#xD;
             50,000 cell/mcL), history of bleeding diathesis or coagulopathy, or hypercoagulable&#xD;
             states&#xD;
&#xD;
         12. Hemodynamic or respiratory instability requiring inotropic support, mechanical&#xD;
             ventilation or mechanical heart assistance within 30 days before randomization&#xD;
&#xD;
         13. Hypertrophic cardiomyopathy with obstruction&#xD;
&#xD;
         14. Ventricular dysfunction with lleft ventricular ejection fraction &lt; 30%&#xD;
&#xD;
         15. Cardiac imaging (echo, CT, and/or MRI) evidence of intracardiac mass, thrombus or&#xD;
             vegetation&#xD;
&#xD;
         16. Inability to tolerate or condition precluding treatment with anti-&#xD;
             thrombotic/anticoagulation therapy during or after the valve implant procedure&#xD;
&#xD;
         17. Stroke or transient ischemic attack within 90 days before randomization&#xD;
&#xD;
         18. Renal insufficiency (eGFR &lt; 30 ml/min per the Cockcroft-Gault formula) and/or renal&#xD;
             replacement therapy&#xD;
&#xD;
         19. Active bacterial endocarditis within 180 days of randomization&#xD;
&#xD;
         20. Severe lung disease (FEV1 &lt; 50%) or currently on home oxygen&#xD;
&#xD;
         21. Severe pulmonary hypertension (e.g., pulmonary arterial systolic pressure ≥ 2/3&#xD;
             systemic pressure)&#xD;
&#xD;
         22. History of cirrhosis or any active liver disease&#xD;
&#xD;
         23. Significant abdominal or thoracic aortic disease (such as porcelain aorta, aneurysm,&#xD;
             severe calcification, aortic coarctation, etc.) that would preclude safe passage of&#xD;
             the delivery system or cannulation and aortotomy for surgical AVR.&#xD;
&#xD;
         24. Hostile chest or conditions or complications from prior surgery that preclude safe&#xD;
             reoperation (e.g., mediastinitis, radiation damage, abnormal chest wall, adhesion of&#xD;
             aorta or internal mammary artery to sternum, etc.)&#xD;
&#xD;
         25. Patient refuses blood products&#xD;
&#xD;
         26. BMI &gt; 50 kg/m^2&#xD;
&#xD;
         27. Estimated life expectancy &lt; 24 months&#xD;
&#xD;
         28. Absolute contraindications or allergy to iodinated contrast agent that cannot be&#xD;
             adequately treated with pre-medication&#xD;
&#xD;
         29. Immobility that would prevent completion of study procedures&#xD;
&#xD;
         30. Currently participating in an investigational drug or another device study.&#xD;
&#xD;
         31. Pregnancy or lactation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hélène Eltchaninoff, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Rouen - Hopital Charles Nicolle</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Didier Tchétché, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Pasteur Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Sigmund, Dr.</last_name>
    <phone>+49 89 800 650</phone>
    <phone_ext>0</phone_ext>
    <email>michael.sigmund@cro-sss.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christine Schubert, Dr.</last_name>
    <phone>+49 89 800 650</phone>
    <phone_ext>0</phone_ext>
    <email>christine.schubert@cro-sss.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>LKH-Univ. Klinikum Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätskliniken Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum St. Pölten - Lilienfeld</name>
      <address>
        <city>St. Pölten</city>
        <zip>3100</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus der Stadt Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nicosia General Hospital</name>
      <address>
        <city>Nicosia</city>
        <zip>1450</zip>
        <country>Cyprus</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University hospital Hradec Králové</name>
      <address>
        <city>Hradec Králové</city>
        <zip>50005</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nemocnice Na Homolce</name>
      <address>
        <city>Praha 5</city>
        <zip>150 30</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IKEM (Institut Klinické a Experimentální Medicíny)</name>
      <address>
        <city>Praha</city>
        <zip>140 21</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helsinky University Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux - Hôpital cardiologique du Haut-Lévêqu</name>
      <address>
        <city>Bordeaux</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Lille - Institute Coeur Poumon</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Jacques Cartier</name>
      <address>
        <city>Paris</city>
        <zip>91300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU et Université de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Rennes - Hopital de Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Rouen - Hopital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik der Ruhr-Universität Bochum</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt Am Main</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitäres Herz- und Gefäßzentrum UKE Hamburg GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitäres Herzzentrum Lübeck</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. James´s Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale del Cuore G. Pasquinucci</name>
      <address>
        <city>Massa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universita di Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Integrata Verona</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis Eindhoven</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <zip>2333</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Antonius Ziekenhuis Nieuwegein</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3445 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inselspital Universitätsspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hirslanden Klinik Im Park</name>
      <address>
        <city>Zürich</city>
        <zip>8027</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Golden Jubilee National Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G81 4DY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Cyprus</country>
    <country>Czechia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 6, 2019</study_first_submitted>
  <study_first_submitted_qc>November 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2019</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Research in woman</keyword>
  <keyword>Transcatheter Aortic Valve Implantation (TAVI)</keyword>
  <keyword>surgical aortic valve replacement (SAVR)</keyword>
  <keyword>cardiovascular disease</keyword>
  <keyword>heart disease</keyword>
  <keyword>Sapien 3</keyword>
  <keyword>Transcatheter Aortic Valve Replacement (TAVR)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

